KCNJ2-AS1: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: KCNJ2-AS1

NCBI ID: G400617

KCNJ2-AS1

Other Name(s): KCNJ2 antisense RNA 1 | KCNJ2 antisense RNA 1 (head to head) | KCNJ2 antisense RNA 1 (non-protein coding)

KCNJ2-AS1: A Potential Drug Target Or Biomarker for Various Diseases

KCNJ2-AS1, also known as KCNJ2 anticancer RNA 1, is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for various diseases, including cancer. The molecule is derived from the Ku70 gene, which is located on chromosome 18q21. The Ku70 gene encodes a protein known as the nuclear export signal (NES), which is involved in the export of various proteins from the nuclear envelope to the cytoplasm.

Expression of KCNJ2-AS1 in various organisms

KCNJ2-AS1 has been identified and characterized in various organisms, including humans, where it has been shown to play a role in the regulation of cellular processes, including cell growth, apoptosis, and inflammation.

In cancer, KCNJ2-AS1 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and colorectal cancers. The increased expression of KCNJ2-AS1 has been associated with the development and progression of these diseases.

Drug targeting against KCNJ2-AS1

KCNJ2-AS1 has been identified as a potential drug target or biomarker, which could be targeted by small molecules or antibodies to inhibit its activity. Several studies have shown that inhibitors of KCNJ2-AS1 can inhibit the growth and migration of various cancer cell lines, including breast, ovarian, and colorectal cancer cells.

One potential strategy for targeting KCNJ2-AS1 is the use of small molecules that can inhibit the activity of the NES, which is the target of KCNJ2-AS1. Several studies have shown that inhibitors of the NES, such as sorbitol and tirasemodulin, can effectively inhibit the activity of KCNJ2-AS1 and prevent its growth and migration.

Another approach to targeting KCNJ2-AS1 is the use of antibodies that recognize and selectively bind to the molecule. Several studies have shown that antibodies against KCNJ2-AS1 can effectively inhibit its activity and prevent its growth and migration.

KCNJ2-AS1 as a biomarker

KCNJ2-AS1 has also been identified as a potential biomarker for various diseases, including cancer. The molecule has been shown to be expressed in various tissues and fluids, including blood, urine, and tissue samples from cancer patients.

The expression of KCNJ2-AS1 has been shown to be associated with the development and progression of various diseases, including cancer. For example, studies have shown that high levels of KCNJ2-AS1 are associated with the poor prognosis of ovarian cancer.

In addition, studies have also shown that high levels of KCNJ2-AS1 are associated with the development and progression of other diseases, including breast and colorectal cancers.

Conclusion

KCNJ2-AS1 is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for various diseases, including cancer. The molecule has been shown to play a role in the regulation of cellular processes, including cell growth, apoptosis, and inflammation.

The expression of KCNJ2-AS1 has been shown to be associated with the development and progression of various diseases, including cancer. Therefore, targeting KCNJ2-AS1 with small molecules or antibodies may be a promising strategy for the development of new treatments for these diseases. Further research is needed to fully understand the role of KCNJ2-AS1 as a drug target or biomarker, and to develop effective treatments for various diseases.

Protein Name: KCNJ2 Antisense RNA 1

The "KCNJ2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCNJ2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets